
Durvalumab Plus BCG Improves Survival in Early Bladder Cancer
Treatment with the combination of durvalumab (Imfinzi) and standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy led to a statistically significant and clinically meaningful improvement in disease-free survival (DFS) when used …